Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact
Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact

Differentiation of ATTR amyloidosis based on abdominothoracic organ-specific uptakeof 124I-AT-01 (124I-p5+14)assessed by PET/CT imaging

Sep 6, 2022 Posters & Publications

AUTHORS: Stuckey, Alan1, Martin, Emily1, Heidel, R Eric1, Kennel, Stephen1, Perk, Timothy2, Weisman, Amy J2, Wall, Jonathan1 1 University of Tennessee Graduate School of Medicine, USA 2 AIQ Solutions, USA Click Here to View...

Quantitative changes in organ-specific amyloid load in a patient with AL amyloidosis,measured by 124I-AT-01 PET/CT imaging, correlate with serumbiomarkers

Sep 6, 2022 Posters & Publications

AUTHORS: Stuckey, Alan1, Martin, Emily1, Heidel, R Eric1, Kennel, Stephen1, Perk, Timothy2, Weisman, Amy J2, Wall, Jonathan1 1 University of Tennessee Graduate School of Medicine, USA 2 AIQ Solutions, USA Click Here to View...

Quantification of left ventricular amyloid using 124I-p5+14 (AT-01) and 18F-florbetapir positron emission tomography in AL and ATTR amyloidosis

Sep 6, 2022 Posters & Publications

AUTHORS: Clerc, Olivier F.1, Falk, Rodney H.1, Cuddy, Sarah A. M.1, Benz, Dominik C. 1, Taylor, Alexandra1, Canseco Neri, Jocelyn1, Robertson, Matthew2, Newsom, James D.2, Kijewski, Marie Foley2, Dicarli, Marcelo F. 2, Bianchi, Giada1, Dorbala, Sharmila1,2 1 Cardiac...

Results of the first-in-human PET/CT imaging study of the amyloid-reactive peptide 124I-AT-01 (124I-p5+14) for the detection of systemic amyloidosis

Sep 5, 2022 Posters & Publications

AUTHORS: Jonathan S. Wall1, Emily B. Martin1, Alan Stuckey1, Dustin Powell2, Tina Richey1, Angela Williams1, R. Eric Heidel3, Ronald Lands1, Stephen J. Kennel1 Departments of Medicine1, Radiology2 and Surgery3, University of Tennessee Graduate School of Medicine, TN,...

Pan-amyloid reactivity of radioiodinated peptide 124I-AT-01 in patients with systemic amyloidosis demonstrated by PET/CT imaging

Sep 5, 2022 Posters & Publications

AUTHORS: Emily B. Martin1, Alan Stuckey1, Dustin Powell2, Ronald Lands2, Spencer Guthrie3, Stephen J. Kennel1, and Jonathan S. Wall1 1 University of Tennessee Graduate School of Medicine, Knoxville, TN, USA 2 University of Tennessee Medical Center, Knoxville, TN, USA...
« Older Entries
Next Entries »

Recent Posts

  • Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
  • Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
  • Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis
  • Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
  • Accurate Quantitation of Cardiac Amyloidosis by 124I-Evuzamitide Compared to Extracellular Volume

Recent Comments

No comments to show.
COMPANY
About
Management Team
Board of Directors
Scientific Advisory Board
Investors

SCIENCE
Approach
PAR Therapeutics

PIPELINE

NEWS
Press Releases
Posters & Publications

AMYLOIDOSIS
CAREERS
CONTACT

  • Privacy Policy
  • Terms of Service
  • Follow
  • Follow
Attralus logo

Attralus, Inc.
365 Fifth Ave South, Ste 208
Naples, FL 34102

©2026 Attralus, Inc.  All Rights Reserved.